Unlike most of the published reports showing that several surface markers used to identify ovarian CSCs, such as CD24 [6], CD44 [7], CD117 [8], and CD133 [9], we have unveiled the ACTL6A had poor prognosis and correlated enrichment of CSCs in ovarian cancer. This evidence concerns the gene KIT and ovarian carcinoma.